Overview Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast
cells (MCs) in extra‐cutaneous organs. Diagnosis The major criterion is presence of …

Systemic mastocytosis (SM) has greatly benefited from the broad application of precision
medicine techniques to hematolymphoid neoplasms. Sensitive detection of the recurrent KIT …

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …

Background The WHO classification separates mastocytosis into distinct variants, but
prognostication remains a clinical challenge. The aim of this study was to improve …

Mastocytosis is a neoplasm characterized by a clonal proliferation of mast cells, which
accumulate in one or multiple organs, associated with an extremely heterogeneous clinical …

Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by≥ 20% mast
cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the …

Based on new data and increased understanding of disease molecular genetics, the
international consensus classification (ICC) has made several changes in the diagnosis and …

In the current classification of the World Health Organization (WHO), bone marrow
mastocytosis (BMM) is a provisional variant of indolent systemic mastocytosis (ISM) defined …

Avapritinib, a highly selective inhibitor of KIT D816V, was approved by the Food and Drug
Administration in 2021 for treatment of advanced systemic mastocytosis (AdvSM) and by the …

Background Several risk stratification models have been proposed in recent years for
systemic mastocytosis but have not been directly compared. Here we designed and …